Other languages Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
4.78 ^USD	-0.21%		-15.25%	+27.81%

Mar. 21	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI
Mar. 19	Fate Therapeutics Prices $100 Million Offering, Private Placement	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fate Therapeutics Prices $100 Million Offering, Private Placement	Mar. 19
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors	Jan. 08
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Yu-Waye Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023	23-06-08
Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03
Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023	23-05-03
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
BB Biotech bestätigt Verlust für 2022 - Erwartet mehr Aktivität 2023	23-02-17
Century Therapeutics' Pipeline Prioritization Plans Indicate Declining Natural Killer Cell Hype, Chardan Research Says	23-01-06
Top Midday Decliners	23-01-06
December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures	23-01-06
Top Premarket Decliners	23-01-06
Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023	23-01-05
Fate Therapeutics, Inc. Receives Notice of Termination from Janssen Biotech,Inc. of the Collaboration and Option Agreement Dated April 2, 2020	23-01-05
GT Biopharma, Fate Therapeutics Say Preclinical Data Shows Potential of New Approach to Treat Leukemia	22-12-12
Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy	22-12-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Other languages

Filters